Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An assessment of pexelizumab in acute myocardial infarction (APEX-AMI) substudy

American Heart Journal

Volumn 160, Issue 2, 2010, Pages 272-278

  Ezekowitz, Justin A ^a,e   Armstrong, Paul W ^a   Granger, Christopher B ^b   Theroux, Pierre ^c   Stebbins, Amanda ^b   Kim, Raymond J ^d   Patel, Manesh R ^b,d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c MONTREAL HEART INSTITUTE   (Canada)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e FRCPC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; PEXELIZUMAB;

ADULT; AGED; ARTICLE; BLOOD VESSEL OCCLUSION; ELECTROCARDIOGRAM; FEMALE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE WALL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NO REFLOW PHENOMENON; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RISK ASSESSMENT; SINGLE-CHAIN ANTIBODIES; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 77955441883     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.05.035     Document Type: Article

References (28)

1. Antman E.M., Anbe D.T., and Armstrong P.W. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Circulation 110 2004 e82 e292
2. Ezekowitz J.A., Theroux P., and Chang W. N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction Can J Cardiol 22 2006 393 397
3. Ezekowitz J.A., Theroux P., and Welsh R. Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline? Can J Physiol Pharmacol 85 2007 173 178
4. Mega J.L., Morrow D.A., and de Lemos J.A. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy J Am Coll Cardiol 44 2004 335 339
5. Cochet A., Zeller M., and Cottin Y. The extent of myocardial damage assessed by contrast-enhanced MRI is a major determinant of N-BNP concentration after myocardial infarction Eur J Heart Fail 6 2004 555 560
6. Ezekowitz J.A., Kaul P., and Bakal J.A. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction J Am Coll Cardiol 53 2009 13 20
7. Kim R.J., Wu E., and Rafael A. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction N Engl J Med 343 2000 1445 1453
8. Wu K.C., Zerhouni E.A., and Judd R.M. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction Circulation 97 1998 765 772
9. Armstrong P.W., Granger C.B., and Adams P.X. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial JAMA 297 2007 43 51
10. Patel M.R., Worthley S.G., and Stebbins A. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary PCI: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI Trial J Am Coll Cardiol 2009
11. Wu E., Judd R.M., and Vargas J.D. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction Lancet 357 2001 21 28
12. Kim R.J., Shah D.J., and Judd R.M. How we perform delayed enhancement imaging J Cardiovasc Magn Reson 5 2003 505 514
13. Mahaffey K.W., Reist C.J., and Fu Y. Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library Contemp Clin Trials 29 2008 887 895
14. Brener S.J., Moliterno D.J., and Aylward P.E. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study Eur Heart J 29 2008 1127 1135
15. Lee K.L., Woodlief L.H., and Topol E.J. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators Circulation 91 1995 1659 1668
16. Epstein A.E., DiMarco J.P., and Ellenbogen K.A. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons Circulation 117 2008 e350 e408
17. Hohnloser S.H., Kuck K.H., and Dorian P. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction N Engl J Med 351 2004 2481 2488
18. Flather M.D., Yusuf S., and Kober L. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients Lancet 355 2000 1575 1581
19. Cannon C.P., Braunwald E., and McCabe C.H. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
20. Pitt B., Remme W., and Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [see comment][erratum appears in N Engl J Med. 2003 May 29;348(22):2271] N Engl J Med 348 2003 1309 1321
21. Freemantle N., Cleland J., and Young P. β-Blockade after myocardial infarction: systematic review and meta regression analysis BMJ 318 1999 1730 1737
22. White H.D., Norris R.M., and Brown M.A. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction Circulation 76 1987 44 51
23. Wu E., Ortiz J.T., Tejedor P., and Lee D.C. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study Heart 94 2008 730 736
24. Hindman N.B., Schocken D.D., and Widmann M. Evaluation of a QRS scoring system for estimating myocardial infarct size. V. Specificity and method of application of the complete system Am J Cardiol 55 13 Pt 1 1985 1485 1490
25. Gibbons R.J., Valeti U.S., and Araoz P.A. The quantification of infarct size J Am Coll Cardiol 44 2004 1533 1542
26. Gibbons R.J., Miller T.D., and Christian T.F. Infarct size measured by single photon emission computed tomographic imaging with 99mTc-sestamibi: a measure of the efficacy of therapy in acute myocardial infarction Circulation 101 2000 101 108
27. Atar D., Petzelbauer P., and Schwitter J. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial J Am Coll Cardiol 53 2009 720 729
28. Orn S., Manhenke C., and Greve O.J. Microvascular obstruction is a major determinant of infarct healing and subsequent left ventricular remodelling following primary percutaneous coronary intervention Eur Heart J 2009 ehp219